Adicet Bio, Inc. ACET
2.46 USD -0.04 (-1.60%)
Regular-session close
2.44 -0.02 -0.81%
After hours · Nov 19, 4:00 PM ET
2.42 Day range 2.62
2.40 52-week range 11.15
- YTD
- -70.78%
- 1 year
- -73.35%
News
benzinga.com Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $55 Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $90 to $55.
benzinga.com Adicet Bio Q3 EPS $(1.76) Misses $(1.59) Estimate Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.76) per share which missed the analyst consensus estimate of $(1.59) by 10.69 percent. This is a 62.07 percent increase over losses of…
businesswire.com Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies…
businesswire.com Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies…
marketbeat.com Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months Adicet Bio NASDAQ: ACET reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including…
businesswire.com Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies…
seekingalpha.com Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
businesswire.com Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies…
businesswire.com Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies…
zacks.com Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the…
zacks.com Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
gurufocus.com Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies
businesswire.com Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies…
businesswire.com Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies…
businesswire.com Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies…
businesswire.com Adicet Bio Announces FDA Clearance of IND Application for ADI-212 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies…
zacks.com Here's Why You Should Add ACET Stock to Your Portfolio Now Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
zacks.com Are Medical Stocks Lagging Adicet Bio (ACET) This Year? Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
seekingalpha.com Adicet Bio: A Cheap Gamma Delta T-Cell Play Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus…
zacks.com Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
marketbeat.com Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus…
zacks.com All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
